PALI — Palisade Bio Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Palisade Bio Inc

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$1.83
Market Cap$315M
Float128.4M
Shares Outstanding173.6M
P/E (TTM)15.13
Price/Sales (TTM)11.78
vs. Analyst Target+430.8% to analyst PT
Dividend RateNone
Analyst Target Price$9.71 (3 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $13,520 -$10.3M -$146,000 -$9.9M
2021 N/A -$26.6M -$168,000 -$24.2M
2022 $250,000 -$14.3M -$167,000 -$14.2M
2023 $250,000 -$12.3M $250,000 -$12.3M
2024 N/A -$14.4M -$3,000 -$14.4M
2025 N/A -$16.8M -$3,000 -$16.8M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$2.8M
Sep 2025 N/A -$2.9M
Dec 2025 N/A -$8.9M
Mar 2026 N/A -$9.6M

Ownership & Float

Insider Ownership0.0%
Institutional Ownership81.2%
Short Float20.4%
% of All Funds Holding1.03%
Number of Funds Holding85

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$1.96Near-term / short-term trend
Weekly40-Week SMA$1.69Medium-term trend
Weekly80-Week SMA$1.43Cyclical trend (business cycle)
Weekly200-Week SMA$20.89Secular trend (multi-year)
Monthly10-Month SMA$1.69Near-term monthly trend
Monthly20-Month SMA$1.49Medium-term monthly trend
Monthly40-Month SMA$7.78Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$2.30 resistance 1.34x 3 months ago
$1.10 support 6.58x 6 months ago
$2.40 resistance 4.83x 16 months ago
$7.90 resistance 1.44x 23 months ago

Historical Earnings Reactions (72 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.74% 0.00% 44.44% 9.38% -8.70%
1 Day -0.59% 0.00% 40.28% 36.18% -19.13%
1 Week -1.45% -0.72% 43.06% 54.07% -44.75%
2 Weeks -1.36% -3.14% 34.72% 51.19% -34.67%
1 Month 1.05% -2.92% 44.44% 84.00% -44.88%

Next earnings: May 11, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan1.0%57.9%19
Feb-3.1%47.4%19
Mar-0.4%42.1%19
Apr-3.2%45.0%20
May-8.7%26.3%19
Jun-5.3%26.3%19
Jul-8.4%42.1%19
Aug-9.2%36.8%19
Sep7.4%52.6%19
Oct-3.2%21.1%19
Nov0.0%42.1%19
Dec1.8%47.4%19

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.02% 41.7% 904
Tuesday -0.10% 38.0% 988
Wednesday 0.02% 42.7% 986
Thursday 0.14% 40.0% 967
Friday -0.40% 38.3% 963

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 81.2%

Insider Transactions — Smart Summary

Total insider ownership: 0.0%

12-Month Insider Activity Summary

Total Filings4
Net Value-$10,298.75
Net Shares Change25,448
% of Float0.0%
C-Suite Filings2
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Williams Donald Allen +$17,756 2 2 buy
Finley John David CEO, CFO -$6,818 1 1 sell
Jones Mitchell Lawrence Chief Medical Officer -$3,480.75 1 1 sell

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-21 Williams Donald Allen +$8,356 Transaction at $1.67, now +9.5%
2026-01-13 Williams Donald Allen +$9,400 Transaction at $1.88, now -2.7%
2026-02-13 Jones Mitchell Lawrence Chief Medical Officer -$3,480.75 Transaction at $1.75, now +4.6%
2026-02-13 Finley John David CEO, CFO -$6,818 Transaction at $1.75, now +4.6%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Palisade Bio Inc (PALI) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for PALI on Trend Edge →